Innovative blood test for cancer of Johnson and Johnson: Innovative Blood
A new test can be seen a single cancer cell among billions of healthy cells in a small blood sample in development. Green, Johnson & Johnson, Ortho Biotech Oncology Research and Development (ORD), a unit of Johnson & Johnson Pharmaceutical R & D collaboration with researchers from the Massachusetts work General Hospital (MGH, Boston, MA) on the test set on the market.
The first prototype was developed by a team of doctors, engineers and biologists, Dr. Daniel Haber and Toner Mamet at Massachusetts General Hospital was conducted first reported in 2007, was developed. The test detected circulating blood cancer tumor cells (CTC), cancer cells, the release of the tumor, and is carried out away from the blood stream. These CTCs are extremely rare, can any of billions of healthy cells examined blood cancer be detected.
Toner and thousands CTC-chip with blood cancer miniature column with antibodies coated bind with the CCT has designed. When a blood sample passed over the chip, go normal cells, but stick CTC. Special stains, the researchers can then count the number of CTCs in the blood sample of a patient.
This test can be used to make blood cancer rapid decisions physicians be continued as in the treatment of cancer patients. When a doctor gives a particular drug and the number of cancer cells in the blood drops of the patient, the doctor will stay with this treatment. If increasing the number of circulating cancer cells in the blood or stay the same, the doctor may switch to another drug and may work better to kill the cancer.
For example, doctors can give a drug or radiation treatment and then run to see CT months later, when the patient's tumor has decreased in size. A patient cannot adapt to live more than a few laps on the treatment, if they should wait to see whether a change in the size of the tumor can be detected. While the TC is a full-body X-rays, the CTC-chip is simple and requires only a few tablespoons of blood and can determine if the treatment was successful before.
The CTC-chip was tested experimentally in 200 cancer patients. A donation of $ 15 million from the American Association for Cancer Research (AACR), the Stand Up to Cancer telethon will enable researchers from four major research institutions to examine the test in cancer patients. These institutions are: the Massachusetts General Hospital (Boston, MA), University of Texas MD Anderson Cancer Center (Houston, TX), Dana-Farber Cancer Institute (Boston, MA) and the Memorial Sloan-Kettering Cancer Center (New York, New York).
At this point, the chip is able to expensive (about $ 500) and requires experience. Collaboration with Johnson & Johnson to help researchers to find ways around the MGH chip faster, cheaper, more sensitive and easier to use by doctors. Hopes are high. This chip is the way is diagnosed and treated in the near future.
A new test can be seen a single cancer cell among billions of healthy cells in a small blood sample in development. Green, Johnson & Johnson, Ortho Biotech Oncology Research and Development (ORD), a unit of Johnson & Johnson Pharmaceutical R & D collaboration with researchers from the Massachusetts work General Hospital (MGH, Boston, MA) on the test set on the market.
The first prototype was developed by a team of doctors, engineers and biologists, Dr. Daniel Haber and Toner Mamet at Massachusetts General Hospital was conducted first reported in 2007, was developed. The test detected circulating blood cancer tumor cells (CTC), cancer cells, the release of the tumor, and is carried out away from the blood stream. These CTCs are extremely rare, can any of billions of healthy cells examined blood cancer be detected.
Toner and thousands CTC-chip with blood cancer miniature column with antibodies coated bind with the CCT has designed. When a blood sample passed over the chip, go normal cells, but stick CTC. Special stains, the researchers can then count the number of CTCs in the blood sample of a patient.
This test can be used to make blood cancer rapid decisions physicians be continued as in the treatment of cancer patients. When a doctor gives a particular drug and the number of cancer cells in the blood drops of the patient, the doctor will stay with this treatment. If increasing the number of circulating cancer cells in the blood or stay the same, the doctor may switch to another drug and may work better to kill the cancer.
For example, doctors can give a drug or radiation treatment and then run to see CT months later, when the patient's tumor has decreased in size. A patient cannot adapt to live more than a few laps on the treatment, if they should wait to see whether a change in the size of the tumor can be detected. While the TC is a full-body X-rays, the CTC-chip is simple and requires only a few tablespoons of blood and can determine if the treatment was successful before.
The CTC-chip was tested experimentally in 200 cancer patients. A donation of $ 15 million from the American Association for Cancer Research (AACR), the Stand Up to Cancer telethon will enable researchers from four major research institutions to examine the test in cancer patients. These institutions are: the Massachusetts General Hospital (Boston, MA), University of Texas MD Anderson Cancer Center (Houston, TX), Dana-Farber Cancer Institute (Boston, MA) and the Memorial Sloan-Kettering Cancer Center (New York, New York).
At this point, the chip is able to expensive (about $ 500) and requires experience. Collaboration with Johnson & Johnson to help researchers to find ways around the MGH chip faster, cheaper, more sensitive and easier to use by doctors. Hopes are high. This chip is the way is diagnosed and treated in the near future.
